{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:53:16Z","timestamp":1780959196717,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.jaad.2004.09.016","type":"journal-article","created":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T07:33:59Z","timestamp":1107243239000},"page":"240-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study"],"prefix":"10.1016","volume":"52","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"F\u00f6lster-Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"de Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles J.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Goertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2004.09.016_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200321020-00003","article-title":"Cost of illness of atopic dermatitis in children: a societal perspective","volume":"21","author":"Kemp","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jaad.2004.09.016_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2133.2001.03960.x","article-title":"The infants' dermatitis quality of life index","volume":"144","author":"Lewis-Jones","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib3","first-page":"225","article-title":"Topical steroid treatment in infants, children and adolescents","volume":"9","author":"Hepburn","year":"1994","journal-title":"Adv Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000992280003900101","article-title":"Managing pediatric atopic dermatitis","volume":"39","author":"Raimer","year":"2000","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.jaad.2004.09.016_bib5","first-page":"1643","article-title":"Systemic side-effects of topical preparation in children","volume":"58","author":"Saurat","year":"1982","journal-title":"Sem Hop"},{"key":"10.1016\/j.jaad.2004.09.016_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1525-1470.1984.tb01124.x","article-title":"Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis in childhood","volume":"1","author":"Queille","year":"1984","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1986.tb06242.x","article-title":"Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease","volume":"115","author":"Turpeinem","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2133.1988.tb02461.x","article-title":"Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children","volume":"118","author":"Turpeinem","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib9","first-page":"949","article-title":"Minimising the use of topical steroids in infants","volume":"232","author":"Morley","year":"1988","journal-title":"Practitioner"},{"key":"10.1016\/j.jaad.2004.09.016_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1525-1470.1988.tb00904.x","article-title":"Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children","volume":"5","author":"Turpeinen","year":"1988","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1440-0960.1996.tb01070.x","article-title":"Compliance problems in pediatric atopic eczema","volume":"37","author":"Fischer","year":"1996","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.2000.03473.x","article-title":"Topical corticosteroid phobia in patients with atopic eczema","volume":"142","author":"Charman","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000018495","article-title":"Why do patients with atopic dermatitis refuse to apply topical corticosteroids?","volume":"201","author":"Fukaya","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2004.09.016_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2133.1999.02974.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology","volume":"141","author":"Grassberger","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/sder.2001.29066","article-title":"Pimecrolimus (Elidel, SDZ ASM 981) \u2013 preclinical pharmacologic profile and skin selectivity","volume":"20","author":"Stuetz","year":"2001","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2004.09.016_bib16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2165\/00003495-200262050-00007","article-title":"Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis","volume":"62","author":"Wellington","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2004.09.016_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2133.1997.tb03788.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology","volume":"137","author":"Meingassner","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib18","first-page":"257","article-title":"Pimecrolimus is more cell-selective than corticosteroids: in vivo and in vitro data","volume":"16","author":"Kalthoff","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2004.09.016_bib19","first-page":"1S701","article-title":"Pimecrolimus (SDZ ASM 981) does not affect Langerhans cells in murine epidermis, in contrast to corticosteroids","volume":"129","author":"Meingassner","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2004.09.016_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","article-title":"The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study","volume":"144","author":"Queille-Roussel","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000051813","article-title":"Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis","volume":"204","author":"Van Leent","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2004.09.016_bib22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1046\/j.1365-2133.2001.04133.x","article-title":"First experience of topical SDZ ASM 981 in children with atopic dermatitis","volume":"144","author":"Harper","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1742-1241.2003.tb10492.x","article-title":"Pimecrolimus: pre-clinical and clinical data","volume":"57","author":"Graham-Brown","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaad.2004.09.016_bib24","unstructured":"Novartis. Elidel (pimecrolimus) Cream 1%. For dermatologic use only. Not for ophthalmic use. Rx only. Prescribing information. Revised April 2003. Available online at: www.pharma.us.novartis.com\/product\/pi\/pdf\/elidel.pdf. Accessed July 21, 2004."},{"key":"10.1016\/j.jaad.2004.09.016_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1542\/peds.110.6.1133","article-title":"The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis","volume":"110","author":"Whalley","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2004.09.016_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mai.2002.126500","article-title":"Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug","volume":"110","author":"Kapp","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2004.09.016_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children","volume":"110","author":"Wahn","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2004.09.016_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mpd.2003.65","article-title":"Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants","volume":"142","author":"Ho","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2004.09.016_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2133.2004.05696.x","article-title":"Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme","volume":"150","author":"Barbier","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib32","first-page":"98","article-title":"Role of some infectious agents in atopic dermatitis","volume":"114","author":"Bonifazi","year":"1985","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.jaad.2004.09.016_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/adc.60.4.338","article-title":"Herpes simplex infections in atopic eczema","volume":"60","author":"David","year":"1985","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2004.09.016_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/adc.61.1.20","article-title":"Bacterial infections in atopic eczema","volume":"61","author":"David","year":"1986","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2004.09.016_bib35","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0190-9622(88)70267-4","article-title":"Increasing incidence of eczema herpeticum: analysis of seventy-five cases","volume":"19","author":"Bork","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1067\/S0190-9622(03)00896-X","article-title":"Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases","volume":"49","author":"Wollenberg","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000018497","article-title":"Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment","volume":"201","author":"Lubbe","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2004.09.016_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archderm.139.5.670","article-title":"Adults with atopic dermatitis and herpes simplex and topical therapy with tacrolimus: what kind of prevention?","volume":"139","author":"Lubbe","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2003.10.247","article-title":"Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination","author":"Papp","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.09.016_bib40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1034\/j.1399-3038.2002.01047.x","article-title":"Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months","volume":"13","author":"Diepgen","year":"2002","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204024910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204024910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:35:42Z","timestamp":1759268142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962204024910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0190962204024910"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2004.09.016","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2004.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}